N/A N=80 Coordinating Pragmatic Primary Care Population Management for Obesity
Obesity · Cardiovascular Risk Factor
Primary: Number of Participants Who Achieved 5% Weight Loss Goal at 6 Months — 6; 6 Participants — p=.85
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
Asthma · Bronchial Diseases · Respiratory Tract Diseases
Primary: Airway Submucosal Inflammatory Cells Ratio Change From Baseline to EOT. — 0.11; 0.75; 1.11; 0.81 Ratio — p=<0.001
Phase 2 N=123 GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
Acute Myeloid Leukemia
Primary: Overall Survival — 4.8; 6.4 months
N/A N=408 Integrating Pharmacogenetics In Clinical Care
Cardiovascular Disease
Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL
N/A N=2,097 Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention
Vaccine Refusal
Primary: Post Intervention Vaccine Intentions — 54; 47; 236; 249 Participants
N/A N=68 Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
Gastroesophageal Reflux Disease (GERD)
Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002
N/A N=466 Teledermatology Mobile App: Patient Facing
Introduction of Teledermatology Mobile Apps
Primary: Total Number of Participants That Successfully Completed Remote Follow up — 51; 182 Participants — p=0.7428
Phase 2 N=574 Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Hemorrhagic Fever, Ebola
Primary: Part 1, Part 2 (Group 2): Number of Participants With Unsolicited Adverse Events — 33; 10; 32; 3 Participants
Phase 2 N=64 Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
Relapsing Multiple Sclerosis
Primary: Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Core Part — 0.0670; 1.0413 lesions per scan — p=<0.001
Phase 3 N=246 A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
Episodic Migraine
Primary: Percentage of Participants With at Least 50% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment) — 30.3; 13.7 Percentage…
Phase 3 N=4 ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection
Infection, Human Immunodeficiency Virus · HIV Infections · Arthralgia
Primary: Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir — 55.045; 42.473; 78.917 Micrograms*hours per…
Early Phase 1 N=12 Treatment of Tendon Injury Using Mesenchymal Stem Cells
Lateral Epicondylitis
Primary: Change From Baseline in Visual Analog Scale (VAS) at 6 and 12 Weeks — 3.57; 3.02; 2.93; 1.60 score on a scale — p=0.52
Phase 2 N=79 ET-01 in Subjects With Lateral Canthal Lines, LCL-207
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 4; 1; 3…
N/A N=684 Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Carcinoma · Renal Cell
Primary: Progression Free Survival (PFS) — 8.394; 6.177 Months
Phase 3 N=70 Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
Peritoneal Cancer
Primary: Efficacy of TEA vs 4Q-TAP in QoR at Postoperative Day (POD)2 — -45; -50 score on a scale